Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
jack jumper ant venom immunotherapy
- Development stage
- Unknown
- Lead developer
- Tasmanian Jack Jumper Allergy Research Group
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Jack jumper ant venom immunotherapy (JJA VIT) is a subcutaneous allergen immunotherapy consisting of purified venom from the jack jumper ant (*Myrmecia pilosula*). It is indicated for the prevention of anaphylaxis in individuals sensitized to jack jumper ant venom, which is a leading cause of severe allergic reactions in south-eastern Australia. The immunotherapy works by gradually desensitizing the patient's immune system to the venom's key allergens, such as Myr p 1 and Myr p 3 (pilosulins), thereby reducing the risk of life-threatening IgE-mediated systemic reactions. The treatment was developed by the Tasmanian Jack Jumper Allergy Research Group and is primarily administered through specialized clinical programs, such as that at the Royal Hobart Hospital, under the auspices of the Tasmanian Government.
- Other names
- Myrmecia pilosula venom immunotherapyjack jumper ant venom extractJJA venom immunotherapy
02
Targets
Allergen-specific CD4+ T cells recognizing Jack Jumper ant venom peptides presented on HLA class IIHigh-affinity immunoglobulin epsilon receptor-bound Immunoglobulin E complexMyrmecia pilosula venom allergens
Beyond the preview
Go deeper on jack jumper ant venom immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on jack jumper ant venom immunotherapy.